Please login to the form below

Not currently logged in
Email:
Password:

glycopyrronium

This page shows the latest glycopyrronium news and features for those working in and with pharma, biotech and healthcare.

AstraZeneca sells Losec rights as part of refocus strategy

AstraZeneca sells Losec rights as part of refocus strategy

its chronic obstructive pulmonary disease (COPD) therapy PT010 (budesonide/glycopyrronium/formoterol fumarate).

Latest news

  • AZ builds case for its COPD triple as it chases GSK’s Trelegy AZ builds case for its COPD triple as it chases GSK’s Trelegy

    In KRONOS, there was a 52% reduction in the rate of moderate or severe COPD exacerbations with Breztri compared with AZ’s two-drug Bevespi glycopyrronium/formoterol fumarate, and a 17% ... Breztri – which combines long-acting beta agonist (LABA)

  • AZ prepares to file COPD triple, taking on rival GSK AZ prepares to file COPD triple, taking on rival GSK

    The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... The data

  • AZ rival to GSK’s COPD drug Anoro fails head-to-head test AZ rival to GSK’s COPD drug Anoro fails head-to-head test

    The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... while AZ’s PT010

  • Dermira craters as acne drug fails late-stage test Dermira craters as acne drug fails late-stage test

    comfort. The fall of DRM01 leaves Dermira with a late-stage candidate called glycopyrronium tosylate for hyperhidrosis or excessive sweating, which could claim FDA approval this year but is considered to

  • AZ’s COPD triple data sets up market clash with GSK AZ’s COPD triple data sets up market clash with GSK

    AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... In Europe it was pipped to

More from news
Approximately 2 fully matching, plus 38 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

Theodora Harold
A snapshot of Crescendo Biologics
PME talks to CEO Theodora Harold...
eyeforpharma Marketing and Customer Innovation Europe
By Richard Springham...
US Drug pricing
The Golden Goose
Why it’s so hard for the US to curb runaway drug prices...

Infographics